Cigna Investments Inc. New decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 76,802 shares of the company’s stock after selling 8,343 shares during the quarter. Johnson & Johnson comprises about 1.2% of Cigna Investments Inc. New’s investment portfolio, making the stock its 11th biggest holding. Cigna Investments Inc. New’s holdings in Johnson & Johnson were worth $11,434,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently made changes to their positions in the business. Verus Financial Partners Inc. increased its position in Johnson & Johnson by 1.7% during the fourth quarter. Verus Financial Partners Inc. now owns 4,382 shares of the company’s stock valued at $639,000 after acquiring an additional 74 shares during the last quarter. Aries Wealth Management increased its position in Johnson & Johnson by 0.3% during the fourth quarter. Aries Wealth Management now owns 27,932 shares of the company’s stock valued at $4,025,000 after acquiring an additional 75 shares during the last quarter. Capital Financial Planning LLC increased its position in Johnson & Johnson by 3.6% during the fourth quarter. Capital Financial Planning LLC now owns 2,192 shares of the company’s stock valued at $320,000 after acquiring an additional 76 shares during the last quarter. Corundum Group Inc. increased its position in Johnson & Johnson by 1.9% during the fourth quarter. Corundum Group Inc. now owns 4,206 shares of the company’s stock valued at $614,000 after acquiring an additional 77 shares during the last quarter. Finally, Portland Global Advisors LLC increased its position in Johnson & Johnson by 0.9% during the third quarter. Portland Global Advisors LLC now owns 8,744 shares of the company’s stock valued at $1,131,000 after acquiring an additional 78 shares during the last quarter. Institutional investors and hedge funds own 67.38% of the company’s stock.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 2,017 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $141.07, for a total transaction of $284,538.19. Following the completion of the sale, the executive vice president now owns 51,736 shares of the company’s stock, valued at $7,298,397.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael E. Sneed sold 58,128 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $149.39, for a total value of $8,683,741.92. Following the sale, the chief operating officer now directly owns 107,511 shares of the company’s stock, valued at approximately $16,061,068.29. The disclosure for this sale can be found here. Insiders own 0.23% of the company’s stock.
NYSE:JNJ opened at $150.13 on Friday. The stock has a 50-day simple moving average of $148.09 and a two-hundred day simple moving average of $136.84. Johnson & Johnson has a 52-week low of $126.10 and a 52-week high of $154.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. The firm has a market capitalization of $395.02 billion, a PE ratio of 17.29, a P/E/G ratio of 2.50 and a beta of 0.69.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $1.88 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.01. Johnson & Johnson had a return on equity of 39.30% and a net margin of 22.18%. The business had revenue of $20.75 billion during the quarter, compared to analyst estimates of $20.83 billion. During the same quarter in the previous year, the company posted $1.97 earnings per share. Johnson & Johnson’s revenue for the quarter was up 1.7% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post 9.03 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 25th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 2.53%. The ex-dividend date of this dividend is Monday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 43.78%.
A number of research firms recently commented on JNJ. Barclays upgraded Johnson & Johnson from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $140.00 to $173.00 in a research report on Thursday, December 19th. Raymond James upped their price objective on Johnson & Johnson from $147.00 to $161.00 and gave the company an “outperform” rating in a research report on Thursday, January 23rd. Cantor Fitzgerald reiterated a “buy” rating and set a $168.00 price objective on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Credit Suisse Group upped their price objective on Johnson & Johnson from $163.00 to $170.00 and gave the company an “outperform” rating in a research report on Monday, January 27th. Finally, Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price objective for the company in a research report on Wednesday, December 18th. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $161.92.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: Why do earnings reports matter?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.